Saturday 17 October 2026
Export DNA’s income statement to Excel — free account
Ginkgo Bioworks Holdings, Inc.
In the quarter to June 2026, revenue fell 48.5%, EPS grew 31.8% and free cash flow fell 16.4%, each against the same quarter a year earlier.
10.27
1.49
−12.67%
Follow DNA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.65 | 2.41 | 2.71 | 5.07 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(13.90) | (7.82) | (9.67) | (25.66) | |
P/B ratio |
1.46 | 0.82 | 0.91 | 1.45 | |
Price to Tangible BV |
1.64 | 0.93 | 1.01 | 1.63 | |
EV/Sales |
2.82 | 0.34 | 0.58 | 2.56 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.19) | (0.31) | (0.57) | (2.47) | |
EV/FCF |
(2.14) | (0.31) | (0.55) | (2.19) | |
Quick Ratio |
4.33 | 4.95 | 4.66 | 4.20 | |
Current Ratio |
4.57 | 5.15 | 4.92 | 4.39 | |
Net Debt/EBITDA |
6.54 | 6.38 | 5.57 | 6.18 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.12 | 0.13 | 0.14 | 0.12 | |
Operating CF/Net income |
0.95 | 0.57 | 0.59 | 0.39 | |
Capex/Depreciation |
(0.21) | (0.15) | 0.06 | 0.00 | |
Research and Development Expense of Revenue |
229.26% | 256.34% | 92.91% | 178.57% | |
Selling, General and Administrative Expense of Revenue |
152.68% | 194.26% | 117.94% | 115.75% | |
Intangible Assets out of Total Assets |
0.04 | 0.05 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
37.68% | 81.41% | 38.97% | 62.65% | |
Graham Net Nets |
(0.39) | (0.49) | (0.30) | (0.15) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(50.55%) | (87.44%) | (67.99%) | (42.73%) | |
Free Cash Flow Yield |
(28.31%) | (45.91%) | (38.66%) | (23.07%) | |
Revenue per Share |
0.32 | 0.33 | 0.97 | 0.70 | |
Operating CF per Share |
(0.71) | (0.78) | (0.86) | (0.57) | |
Capex per Share |
(0.04) | (0.03) | 0.01 | 0.00 | |
Free Cash Flow per Share |
(0.76) | (0.82) | (0.85) | (0.57) | |
Cash per Share |
4.87 | 6.27 | 7.62 | 8.30 | |
Shareholders Equity per Share |
6.77 | 7.44 | 9.17 | 10.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.77 | 7.44 | 9.17 | 10.06 | |
Free Cash Flow |
(46.89) | (48.62) | (47.11) | (31.61) | |
Working Capital |
259.80 | 330.36 | 375.87 | 390.80 | |
Capital Expenditures |
(2.62) | (1.93) | 0.57 | 0.00 | |
Net Current Asset Value |
(237.23) | (179.97) | (139.27) | (123.30) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.13 | 0.10 | (0.01) | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
18.07 | 23.72 | 23.35 | 23.15 | |
Average Payables |
10.39 | 13.79 | 12.37 | 13.20 | |
Average Assets |
1,110.53 | 1,163.27 | 1,248.57 | 1,335.02 | |
Average Common Equity |
516.62 | 545.29 | 612.32 | 678.86 |
Columns are period end dates